论文部分内容阅读
胆囊癌的发病率并不算高,但生物学行为非常恶劣,极易发生局部浸润和远处转移,加之进展缓慢、症状隐匿,大部分胆囊癌在确诊时已经发展到进展期,伴有肝脏浸润、淋巴结转移、远端胆管浸润、胰头部浸润等,目前以吉西他滨、顺铂、卡培他滨、5-氟尿嘧啶(5-FU)为主的化疗、放疗以及新出现的一些靶向治疗药物如厄洛替尼、贝伐单抗、程序性死亡受体1(PD-1)抗体等,对胆囊癌的治疗效果都不佳,尚未有行之有效的药物可提高晚期胆囊癌的存活
The incidence of gallbladder cancer is not high, but the biological behavior is very poor, prone to local infiltration and distant metastasis, combined with the slow progress, the symptoms hiding, most of the gallbladder cancer has been diagnosed at advanced stages, accompanied by the liver Infiltration, lymph node metastasis, distal bile duct infiltration, pancreatic head infiltration, the current gemcitabine, cisplatin, capecitabine, 5-fluorouracil (5-FU) based chemotherapy, radiotherapy and some new emerging targeted therapy Drugs such as erlotinib, bevacizumab, PD-1 antibody and so on, are not effective in treating gallbladder cancer, and no effective drugs have been found to improve the survival of advanced gallbladder cancer